Metabolomics Market (2026-2036)

The growth of this market is mainly driven by the increasing use of metabolomics in biomarker discovery and drug development, the growth of population-scale metabolomic studies linked to genomic and health data, continuous advances in high-resolution mass spectrometry and NMR technologies, and the growing adoption of multiomics approaches in life science research. In addition, the translation of metabolomics into clinical diagnostics and preventive healthcare, the availability of standardized quantitative kits, and the use of artificial intelligence (AI) for metabolite identification and data interpretation are further supporting the growth of this market.

The Metabolomics Market, also referred to as the metabolite profiling market, metabolic phenotyping market, or metabolomics and lipidomics market, comprises the instruments, consumables and kits, software, and services used to identify and quantify small molecules, known as metabolites, in biological samples such as blood, urine, tissue, cells, and microbial and plant samples. The market includes analytical instruments such as liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), capillary electrophoresis-mass spectrometry (CE-MS), mass spectrometry imaging, and NMR spectroscopy systems; consumables such as targeted metabolomics kits, standards, reagents, and columns; software for data processing, metabolite identification, and pathway analysis; and contract metabolomics and lipidomics services. Because metabolites are the downstream products of gene expression, protein activity, diet, the microbiome, drugs, and the environment, metabolomics provides a direct functional readout of the biological state of an organism. The market ecosystem extends from instrument and reagent manufacturers to software developers, service providers, academic and government research institutions, pharmaceutical and biotechnology companies, clinical laboratories, and food, nutrition, and agriculture companies.

The market is experiencing steady growth as metabolomics becomes an essential tool in life science research, drug development, and precision medicine. Metabolic changes are closely associated with diseases such as cancer, cardiovascular and metabolic disorders, neurodegenerative diseases, and inborn errors of metabolism, and metabolite measurements are increasingly used to identify disease mechanisms, discover biomarkers, monitor drug response, and assess toxicity. At the same time, metabolomics is a core component of multiomics research, in which metabolite data are combined with genomic, transcriptomic, and proteomic data to understand how genetic variation and environmental exposures affect health.

Technological advances are expanding the capabilities of metabolomics. Modern high-resolution mass spectrometers offer higher sensitivity, faster acquisition, and better mass accuracy, while ion mobility separation helps distinguish isomeric metabolites and lipids that are difficult to resolve by mass alone. At the American Society for Mass Spectrometry (ASMS) conference in June 2026, Thermo Fisher Scientific introduced the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, Waters launched the Xevo MRT P10 and Cyclic IMS P20 systems for large-scale multiomics and isomer separation, Bruker introduced the timsMRMS system combining trapped ion mobility with FT-ICR mass spectrometry, SCIEX expanded its ZenoTOF 8600 platform, and Shimadzu introduced the LCMS-8065XE triple quadrupole system with AI-enabled workflows. These advances are enabling the measurement of more metabolites in smaller samples and larger studies, supporting demand for new instruments and upgrades across research and clinical laboratories.

Population-scale studies are creating large metabolomic resources and demonstrating the value of metabolomics for disease risk prediction. In November 2025, Nightingale Health completed the release of nuclear magnetic resonance (NMR)-based metabolic profiles for all 500,000 UK Biobank participants to researchers worldwide, creating one of the largest metabolomic datasets linked to genetic and health data. Thermo Fisher Scientific is also supporting the PRECISE-SG100K population health study in Singapore through a strategic collaboration with Precision Health Research, Singapore. These programs combine metabolomic, proteomic, and genomic data with health records, creating opportunities to identify early markers of disease and new drug targets, and generating demand for high-throughput analysis platforms, standardized assays, and data analysis tools.

Clinical translation is an increasingly important growth area. Tandem mass spectrometry is already used routinely in newborn screening for inborn errors of metabolism, and metabolite-based tests are expanding into cardiovascular risk assessment, metabolic health, and preventive care. Nightingale Health has expanded its agreement with Terveystalo to bring its blood analysis to all Terveystalo customers in Finland, with more than 200,000 people having received results through occupational health checks, and in February 2026 received a clinical laboratory permit from the New York State Department of Health. In February 2026, Waters completed its combination with the Biosciences and Diagnostic Solutions businesses of BD, creating a company with about USD 6.5 billion in pro forma 2025 revenue and a dedicated Advanced Diagnostics division focused on regulated clinical workflows, including LC-MS-based multiplex testing. These developments reflect the growing use of mass spectrometry and NMR-based metabolic testing in regulated clinical environments.

The competitive landscape includes large analytical instrument manufacturers, specialized kit and software providers, and contract service providers. Thermo Fisher Scientific, Agilent Technologies, Waters, Bruker, SCIEX (a Danaher company), and Shimadzu lead the instrument segment, while Bruker, JEOL, and other providers offer NMR systems. Leading companies are expanding into consumables, software, and services to provide complete workflows. In June 2025, Bruker acquired biocrates life sciences, an Innsbruck-based provider of mass spectrometry-based quantitative metabolomics kits, assays, software, and services, whose kits cover more than 1,000 metabolites from over 40 metabolite classes, further expanding its multiomics strategy after the acquisitions of PreOmics and Biognosys. Specialized service providers such as Metabolon, which has completed more than 15,000 projects and supported more than 4,000 publications over more than 25 years, and Human Metabolome Technologies in Japan provide metabolomics services to research and pharmaceutical customers.

At the same time, the market faces challenges related to the chemical diversity of metabolites, the difficulty of identifying unknown compounds, and the lack of standardization across platforms and laboratories. The high cost of advanced instruments and the shortage of skilled personnel also limit adoption in some laboratories. As a result, standardized quantitative kits, AI-enabled software for metabolite identification, and complete workflow solutions are expected to play an increasingly important role in market growth over the forecast period.